Pfizer's Conditionally Approved Braftovi Combo Therapy Regime Shows Improved Response In Colorectal Cancer Patients

1. Pfizer's Braftovi shows significant improvement in colorectal cancer trial results. 2. Combination therapy yields 60.9% objective response rate versus 40.0% with standard chemo. 3. Median response duration is 13.9 months, better than 11.1 months with chemotherapy. 4. Ongoing trial may predict favorable overall survival outcomes for Braftovi users. 5. FDA granted accelerated approval for Braftovi in December 2024.